Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 10,005	$ 14,025
Accounts receivable, net of allowance for credit losses	5,124	1,906
Contract assets	1,348	1,604
Inventories	2,558	4,454
Other current assets	892	852
Total current assets	19,927	22,841
Property, plant and equipment, net	11,909	12,166
Other assets	10	18
Total assets	31,846	35,025
Current liabilities
Accounts payable	1,393	1,203
Accrued expenses	1,903	1,765
Current maturities of long-term debt	85	81
Contract liabilities	3,288	4,908
Deposit from purchaser of MesoScribe assets-Note 11		597
Total current liabilities	6,669	8,554
Long-term debt, net of current portion	203	268
Total liabilities	6,872	8,822
Stockholders’ equity:
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,881,838 at September 30, 2024 and 6,824,511 at December 31, 2023	69	68
Additional paid-in capital	29,495	28,695
Accumulated deficit	(4,590)	(2,560)
Total stockholders’ equity	24,974	26,203
Total liabilities and stockholders’ equity	$ 31,846	$ 35,025